The Mayo Clinic’s Program for Rare and Undiagnosed Diseases was first implemented in 2018.
Implementation of the Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD) and the Genetic Testing and Counseling (GTAC) unit, a clinical service model, has helped enable subspecialty practices advance their expertise in rare disease where genetic counselors have not historically been embedded in practice, new study results show.
Findings were published in Journal of Translational Medicine.
Rare diseases affect around 30 million Americans, and although a significant proportion of these conditions has an underlying genetic cause, they can still go undiagnosed.
Recently, the widespread use of social media, support groups for patients and families, and technological advances like next-generation sequencing have led to a better understanding of rare diseases.
However, “lack of awareness of [rare diseases] by doctors and health systems, absent or small registries, and shortage of available biospecimens of patients with [rare disease], limited funding, and scarce opportunities for blockbuster therapies have discouraged clinicians, researchers, policy makers, and pharmaceutical companies to significantly invest in [rare disease].”
The Mayo Clinic’s Center for Individualized Medicine (CIM) implemented PRaUD in 2018 to better serve patients and integrate genomics into subspecialty practice through targeted genetic testing, research, and education, the authors explained.
Subspeciality health care providers from 11 divisions identified patients who underwent targeted multigene panels or custom exome/genome-based panels. To support PRaUD, GTAC was established and launched in 2020 to improve access and increase efficiency for genetic test facilitation, the authors added.
“Patients receive abbreviated point-of-care genetic counseling and testing through a partnership with subspecialty providers,” they said.
To help address the significant shortage of genetic counselors, the GTAC unit also includes these specialists, along with genetic counseling assistants, genetic nurses, and a medical geneticist. To date:
Of the 1152 patients without a confirmed genetic diagnosis included in the study, 50.3% were female and 23.8% were under age 18. Age at the time of clinical genetic testing ranged from 1 year to 87 years.
A total of 617 individuals were offered targeted multigene panels, and custom clinical exome-based panels were completed for 219 individuals. Eighty-nine individuals were offered custom clinical genome-based panels.
“Democratizing access to genetic testing and counseling can broaden the reach of patients with [rare diseases] and increase the diagnostic yield of such indications, leading to better medical management as well as expanding research opportunities,” the authors wrote.
Nearly half of pretest and more than 95% of posttest GTAC appointments were virtual, underscoring the flexibility of this model to have staff work remotely.
“Improved access to genetic counseling and testing via a hybrid telehealth service can increase diagnostic yield, reduce time to diagnosis, and expand reach for [rare disease] indications where testing has been underutilized, ultimately positively impacting a patient’s care,” the researchers added.
Overall, the expansion if PRaUD bridges a critical genetic testing and counseling access gap, they concluded.
Reference
Vairo FPE, Kemppainen JL, Vitek CRR, et al. Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD). J Transl Med. Published online June 23, 2023. doi:10.1186/s12967-023-04183-7
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More